Two randomized trials of the Stellarex DCB for peripheral artery disease continue to show no increase in mortality relative to standard angioplasty at 48 months. One more year of planned follow-up remains.
The controversial suggestion of increased mortality with these devices from an earlier meta-analysis is weaker but still present, albeit with no dose-response relationship and no mechanistic explanation.
Over 100 world experts convened last month at a Vascular Leaders Forum to make sense of a meta-analysis suggesting safety signals with drug elution in peripheral artery disease. Our expert shares what to look for next.
The task force’s draft recommendation against using the ABI to assess for peripheral artery disease in asymptomatic adults would perpetuate underdiagnosis, argues Dr. Heather Gornik.
Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services Policy
Cleveland Clinic vascular specialists explain why this Medicare coverage decision is a big deal and exactly how supervised exercise therapy benefits patients with peripheral artery disease.
Rates of surgery for CLI are going down as rates of endovascular procedures surge. Meanwhile hospital admissions for CLI are holding constant. So reports a huge new nationwide analysis of CLI care.
A large retrospective analysis finds the ankle-brachial index to better predict lower extremity revascularization rates when measured after exercise than at rest. here’s how the lead author says practice should change.